Head and Neck Cancer Treatment in India & UAE

Expert head and neck cancer treatment — organ-preserving surgery, IMRT chemoradiation, and immunotherapy for larynx, pharynx, and oral cavity cancers. Costs 70% lower in India.

Estimated cost: $4,500 – $10,000 · Average stay: 7–14 days

Head and neck squamous cell carcinoma (HNSCC) encompasses cancers of the oral cavity, oropharynx, hypopharynx, larynx, and nasopharynx — together representing approximately 890,000 new cases globally each year, making it the sixth most common cancer worldwide. Despite their common origin in the squamous epithelial lining of the upper aerodigestive tract, these tumors differ substantially in their behavior, prognosis, and optimal treatment depending on the anatomic subsite.

Head and neck cancers broadly split into two etiologic categories: those caused by tobacco and alcohol (predominantly oral cavity, hypopharynx, and larynx) and those caused by human papillomavirus infection (predominantly oropharynx — base of tongue and tonsil). HPV-positive oropharyngeal cancers carry a far better prognosis — 3-year survival exceeding 85% in stage III–IV disease — compared to HPV-negative HNSCC.

The central challenge in head and neck oncology is achieving cancer cure while preserving the functions that define human interaction — speech, swallowing, and breathing. Organ-preservation protocols — concurrent chemoradiation rather than surgery for laryngeal and hypopharyngeal cancers — and robotic surgery (TORS: transoral robotic surgery) for oropharyngeal cancers have transformed treatment, allowing tumor removal through the mouth without external incisions.

India's head and neck oncology programs, centered at Tata Memorial Hospital, Apollo, Fortis, and regional cancer institutes, treat among the world's highest volumes of head and neck cancer patients, creating unparalleled expertise in all treatment modalities.

Types and Key Subsites of Head and Neck Cancer

Head and neck cancers are classified by anatomic subsite:

Oral cavity cancer: lip, tongue, floor of mouth, hard palate, buccal mucosa, and retromolar trigone. Primarily treated by surgery with appropriate adjuvant therapy.

Oropharyngeal cancer: base of tongue, tonsils, soft palate, and posterior pharyngeal wall. HPV-positive: treated with chemoradiation (or TORS for resectable disease at experienced centers). HPV-negative: worse prognosis; more aggressive multimodal treatment.

Laryngeal cancer: supraglottic, glottic (vocal cord), or subglottic. Organ preservation (concurrent chemoradiation) preferred over total laryngectomy for eligible stage III–IV disease.

Hypopharyngeal cancer: piriform sinus, posterior pharyngeal wall, and post-cricoid area. Aggressive behavior with high nodal metastasis rates. Organ preservation or total laryngopharyngectomy.

Salivary gland cancer (see dedicated page).

All HNSCC patients should receive HPV (p16) testing of the tumor specimen — the result profoundly influences prognosis and potentially treatment intensity in future de-escalation strategies.

Who Is a Candidate for Head and Neck Cancer Treatment?

Surgery candidates: oral cavity cancers (most stages), early laryngeal cancers (T1–T2 glottic), and oropharyngeal cancers amenable to TORS. The surgical approach must be capable of achieving adequate margins while preserving critical function.

Definitive chemoradiation candidates: locally advanced laryngeal and hypopharyngeal cancer (where surgery would require total laryngectomy), HPV-positive oropharyngeal cancer (stage III–IVA), and hypopharyngeal cancer. Concurrent platinum-based chemoradiation achieves organ preservation in approximately 60–70% of patients.

Induction chemotherapy (TPF — docetaxel + cisplatin + 5-FU): used before chemoradiation for very bulky stage III–IVA disease to reduce tumor volume and assess chemosensitivity before committing to definitive treatment. The TAX 323 and TAX 324 trials established TPF induction benefit.

First-line metastatic HNSCC: pembrolizumab monotherapy for PD-L1 CPS ≥1 tumors (most HNSCC); pembrolizumab + platinum + 5-FU for CPS ≥1 tumors; and platinum + cetuximab + 5-FU (EXTREME regimen) for PD-L1 negative disease. The KEYNOTE-048 trial established pembrolizumab as first-line standard.

Head and Neck Cancer Treatment: Surgery and Chemoradiation

Surgery for oral cavity cancers: wide local excision with adequate margins + selective neck dissection + free flap reconstruction for large defects (see Oral Cancer page for surgical details).

Transoral robotic surgery (TORS) for oropharyngeal cancer: the da Vinci robotic system allows surgeons to remove base of tongue and tonsillar tumors through the open mouth, avoiding mandibulotomy (jaw-splitting approach) and its associated morbidity. Equivalent oncologic outcomes for selected T1–T2 oropharyngeal tumors. Available at select high-volume head and neck centers in India.

Concurrent chemoradiation for organ preservation: cisplatin (100 mg/m² every 3 weeks × 3, or 40 mg/m² weekly × 6–7) + IMRT (70 Gy primary, 60–66 Gy at-risk nodes, 50 Gy elective nodes, 33–35 fractions). Response is assessed by PET-CT at 12 weeks — complete responders avoid surgery.

Total laryngectomy: when organ preservation fails, total laryngectomy removes the entire larynx. A permanent tracheostomy is formed. Speech is restored via tracheoesophageal puncture (TEP) with prosthesis insertion — achieving near-normal voice quality in most patients.

Planned neck dissection: after definitive chemoradiation, residual PET-positive lymph nodes are dissected. Complete responders (PET-negative nodes) avoid neck dissection.

Procedure Steps

1. Panendoscopy under anesthesia: assess primary tumor extent, synchronous tumors, and obtain representative biopsy with HPV testing.
2. Staging: MRI of primary site; CT chest for lung metastases and synchronous lung cancer; PET-CT for node-positive disease.
3. Multidisciplinary head and neck tumor board: complete treatment plan with surgery + radiation + medical oncology.
4. Dental assessment and dental clearance before radiation.
5. For oral cavity cancers: surgical resection + free flap reconstruction + selective neck dissection.
6. For laryngeal/oropharyngeal organ-preservation: concurrent cisplatin + IMRT for 7 weeks.
7. Response assessment PET-CT at 12 weeks post-chemoradiation.
8. Adjuvant therapy for surgery + pathological high-risk features: cisplatin + radiation 60 Gy.

Head and Neck Cancer Treatment Approaches

Organ-Preserving Chemoradiation

Concurrent IMRT (70 Gy) + weekly or 3-weekly cisplatin for laryngeal, hypopharyngeal, and oropharyngeal cancers. Achieves equivalent survival to surgery with larynx preservation in approximately 60–70% of patients. The treatment of choice for eligible stage III–IV laryngeal cancer (VA Larynx Trial, RTOG 91-11).

Cost: $5,000 – $10,000 (full course)

Transoral Robotic Surgery (TORS)

da Vinci robotic excision of oropharyngeal tumors (base of tongue, tonsil) through the mouth — no external incisions. Reduces morbidity compared to open approaches, shortens hospitalization, and allows faster functional recovery. Available at select Indian cancer centers with robotic surgery programs.

Cost: $5,000 – $10,000

Pembrolizumab + Chemotherapy (Metastatic)

Anti-PD-1 immunotherapy + cisplatin + 5-FU as first-line treatment for metastatic or recurrent HNSCC. KEYNOTE-048 established pembrolizumab superiority over cetuximab + chemotherapy in PD-L1 CPS ≥1 tumors. Response rates of 20–40% with pembrolizumab + chemotherapy.

Cost: $2,000 – $4,500 per cycle

Cetuximab + IMRT (Platinum-Ineligible)

Anti-EGFR targeted therapy combined with IMRT as an alternative to platinum-based chemoradiation in patients ineligible for cisplatin. Based on Bonner trial data showing improved locoregional control vs radiation alone. Note: subsequent trials (RTOG 1016) showed inferiority to cisplatin for HPV-positive oropharyngeal cancer.

Cost: $1,500 – $3,000 per infusion

Cost Comparison Worldwide

Country — Range — Savings

--- — --- — ---

India — $4,500 – $10,000 — Save 70–80%

UAE — $8,000 – $16,000 — Save 55–65%

USA / UK — $30,000 – $80,000+ — Baseline

India's head and neck oncology centers treat more new patients annually than most Western national cancer programs. This experience translates into surgical precision, multimodal expertise, and rehabilitation integration that directly improves outcomes. Complete head and neck cancer treatment — chemoradiation or surgery + adjuvant — costs $8,000–$18,000 total in India, compared to $80,000–$200,000+ in the USA.

Recovery & Follow-up

Recovery depends on the treatment modality. After surgical resection with free flap, hospital stay is 10–14 days with speech and swallowing therapy from day 1. After concurrent chemoradiation, the 7-week treatment course is followed by 4–8 weeks of acute recovery (mucositis, odynophagia resolve). Longer-term recovery focuses on swallowing rehabilitation, voice optimization, and managing xerostomia. Long-term dysphagia is the most significant quality-of-life challenge and is addressed with intensive swallowing therapy.

Recovery Tips

• Speech language pathology therapy should begin from day 1 of treatment — early swallowing exercises prevent fibrosis.
• Meticulous oral hygiene throughout treatment prevents mucositis-related bacterial infections.
• Keep nutritional intake adequate — a PEG (percutaneous endoscopic gastrostomy) tube prevents severe weight loss during chemoradiation.
• Avoid tobacco and alcohol completely — these reduce treatment efficacy and prevent wound healing.
• Trismus (jaw stiffness) from radiation is prevented with daily jaw exercises using a Therabite device or wooden tongue depressors.

Risks & Complications

Surgery risks: wound infection, fistula, free flap failure (3–5%), tracheostomy-related complications, nerve injury. Chemoradiation risks: grade 3 mucositis (30–40%), odynophagia requiring feeding tube, cisplatin nephrotoxicity, and cisplatin-related hearing loss. Long-term risks: xerostomia, dysphagia, trismus, radiation fibrosis, and rare osteoradionecrosis of the jaw.

Why GAF Healthcare

Gaf Healthcare connects head and neck cancer patients with India's highest-volume treatment centers, where multidisciplinary teams — combining surgical oncologists, radiation oncologists, speech pathologists, and dietitians — manage every patient as a complete unit. India's experience in this cancer type is unrivaled, and we ensure patients access this expertise efficiently and affordably.

Frequently Asked Questions

What is the survival rate for head and neck cancer?

HPV-positive oropharyngeal cancer: 5-year survival >80–85% even at stage III–IV. Oral cavity cancer: stage I — 80–85%, stage II — 65–75%, stage III–IV — 30–55%. Laryngeal cancer with organ preservation: 5-year survival 55–75% for stage III–IV. HPV-negative HNSCC has consistently worse prognosis than HPV-positive disease.

What is TORS (transoral robotic surgery)?

TORS uses the da Vinci robotic system to remove oropharyngeal tumors (base of tongue, tonsil) through the open mouth, avoiding external incisions or jaw-splitting approaches. It is appropriate for T1–T2 oropharyngeal tumors in patients who are also candidates for chemoradiation. TORS allows equally good oncologic control with reduced treatment-related morbidity and shorter recovery.

Can I preserve my voice with laryngeal cancer treatment?

For most stage III–IV laryngeal cancer patients, concurrent chemoradiation (the organ-preservation protocol) achieves equivalent 5-year survival to surgery while preserving the larynx in approximately 60–70% of patients. Voice quality with the preserved larynx is typically good. Total laryngectomy, when required, is supplemented by tracheoesophageal voice prosthesis for near-normal speech.

Is HPV testing done for head and neck cancer in India?

Yes. HPV testing (p16 immunohistochemistry as a surrogate for HPV) is standard for all oropharyngeal cancers and is performed at India's top head and neck cancer centers. The result is critical for prognosis and may influence treatment decisions in the context of de-escalation clinical trials.

How long does head and neck cancer chemoradiation treatment last?

Concurrent chemoradiation for head and neck cancer runs for 7 weeks — 35 daily radiation fractions (Monday–Friday), with cisplatin chemotherapy weekly or every 3 weeks during this period. Total time commitment in India for chemoradiation is approximately 8 weeks (including planning before treatment starts).